Although previous work suggests that tamoxifen use only reduced the risk of ERα-positive breast cancer, Yan et al. [17] report that both ERβ1 and ER coregulator SRAP are predictive biomarkers of tamoxifen-response/benefit in women with ERα-negative breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.